Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giuseppe Visani

Showing results (41-50 of 103) with videos related to

Pageof 11
Sort By:
Mediterranean Journal of Hematology and Infectious Diseases|December 4, 2012
Autologous stem cell transplantation for aggressive lymphomasGiuseppe Visani, Paola Picardi, Patrizia Tosi, et al.
Leukemia & Lymphoma|June 24, 2008
R-COMP 21 for frail elderly patients with aggressive B-cell non-Hodgkin lymphoma: a pilot studyGiuseppe Visani, Felicetto Ferrara, Francesco Alesiani, et al.
Expert Review of Hematology|September 18, 2014
The role of the immunosuppressive microenvironment in acute myeloid leukemia development and treatmentAlessandro Isidori, Valentina Salvestrini, Marilena Ciciarello, et al.
Haematologica|February 3, 2004
Clinico-biological features and outcome of acute promyelocytic leukemia patients with persistent polymerase chain reaction-detectable disease after the AIDA front-line induction and consolidation therapyMassimo Breccia, Daniela Diverio, Nélida Inés Noguera, et al.
Leukemia & Lymphoma|September 14, 2004
No preferential sensitivity of t(8;21) acute myeloid leukemias to cytosine arabinoside in vitro: is intensity of therapy or high dose Ara-C crucial for response?Giuseppe Visani, Alessandro Isidori, Tiziana Grafone, et al.
Leukemia Research|October 9, 2017
Low-dose lenalidomide plus cytarabine in very elderly, unfit acute myeloid leukemia patients: Final result of a phase II studyGiuseppe Visani, Felicetto Ferrara, Francesco Di Raimondo, et al.
Haematologica|December 24, 2002
Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of HematologyEmilio Paolo Alessandrino, Sergio Amadori, Giovanni Barosi, et al.
Blood|April 26, 2003
Autologous transplantation of granulocyte colony-stimulating factor-primed bone marrow is effective in supporting myeloablative chemotherapy in patients with hematologic malignancies and poor peripheral blood stem cell mobilizationRoberto M Lemoli, Antonio de Vivo, Daniela Damiani, et al.
Leukemia & Lymphoma|December 16, 2006
An observational study of once weekly intravenous ganciclovir as CMV prophylaxis in heavily pre-treated chronic lymphocytic leukemia patients receiving subcutaneous alemtuzumabGiuseppe Visani, Anna Mele, Barbara Guiducci, et al.
Leukemia & Lymphoma|June 30, 2004
Gemtuzumab ozogamicin for relapsed and refractory acute myeloid leukemia and myeloid sarcomasPier Paolo Piccaluga, Giovanni Martinelli, Michela Rondoni, et al.
Pageof 11

Showing results (41-50 of 103) with videos related to

Sort By:
Pageof 11
Mediterranean Journal of Hematology and Infectious Diseases|December 4, 2012
Autologous stem cell transplantation for aggressive lymphomasGiuseppe Visani, Paola Picardi, Patrizia Tosi, et al.
Leukemia & Lymphoma|June 24, 2008
R-COMP 21 for frail elderly patients with aggressive B-cell non-Hodgkin lymphoma: a pilot studyGiuseppe Visani, Felicetto Ferrara, Francesco Alesiani, et al.
Expert Review of Hematology|September 18, 2014
The role of the immunosuppressive microenvironment in acute myeloid leukemia development and treatmentAlessandro Isidori, Valentina Salvestrini, Marilena Ciciarello, et al.
Haematologica|February 3, 2004
Clinico-biological features and outcome of acute promyelocytic leukemia patients with persistent polymerase chain reaction-detectable disease after the AIDA front-line induction and consolidation therapyMassimo Breccia, Daniela Diverio, Nélida Inés Noguera, et al.
Leukemia & Lymphoma|September 14, 2004
No preferential sensitivity of t(8;21) acute myeloid leukemias to cytosine arabinoside in vitro: is intensity of therapy or high dose Ara-C crucial for response?Giuseppe Visani, Alessandro Isidori, Tiziana Grafone, et al.
Leukemia Research|October 9, 2017
Low-dose lenalidomide plus cytarabine in very elderly, unfit acute myeloid leukemia patients: Final result of a phase II studyGiuseppe Visani, Felicetto Ferrara, Francesco Di Raimondo, et al.
Haematologica|December 24, 2002
Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of HematologyEmilio Paolo Alessandrino, Sergio Amadori, Giovanni Barosi, et al.
Blood|April 26, 2003
Autologous transplantation of granulocyte colony-stimulating factor-primed bone marrow is effective in supporting myeloablative chemotherapy in patients with hematologic malignancies and poor peripheral blood stem cell mobilizationRoberto M Lemoli, Antonio de Vivo, Daniela Damiani, et al.
Leukemia & Lymphoma|December 16, 2006
An observational study of once weekly intravenous ganciclovir as CMV prophylaxis in heavily pre-treated chronic lymphocytic leukemia patients receiving subcutaneous alemtuzumabGiuseppe Visani, Anna Mele, Barbara Guiducci, et al.
Leukemia & Lymphoma|June 30, 2004
Gemtuzumab ozogamicin for relapsed and refractory acute myeloid leukemia and myeloid sarcomasPier Paolo Piccaluga, Giovanni Martinelli, Michela Rondoni, et al.
Pageof 11